Compound Screening Drugs In-Vivo Protein 
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
Drug Discovery World
FEBRUARY 22, 2024
This article is sponsored by Collaborative Drug Discovery. Since its inception, Libra has used CDD Vault as its primary repository for all compound structural data and screening assay results, along with physicochemical and other in vitro biology data and associated metadata generated by its CRO partners.
Drug Discovery World
AUGUST 15, 2023
Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.
Expert insights. Personalized for you.
52 
Let's personalize your content